MARKET

ALT

ALT

Altimmune
NASDAQ
13.00
+0.17
+1.33%
After Hours: 13.45 +0.45 +3.46% 17:44 10/04 EDT
OPEN
13.00
PREV CLOSE
12.83
HIGH
13.18
LOW
12.73
VOLUME
1.27M
TURNOVER
0
52 WEEK HIGH
23.49
52 WEEK LOW
3.830
MARKET CAP
637.33M
P/E (TTM)
-5.8142
1D
5D
1M
3M
1Y
5Y
Altimmune Completes First Dosing for Phase 2 Study of Obesity Drug Candidate
Altimmune Completes First Dosing for Phase 2 Study of Obesity Drug Candidate
MT Newswires · 6d ago
Why NanoVibronix Shares Surged Over 25%; Here Are 82 Biggest Movers From Friday
Gainers Golden Sun Education Group Limited (NASDAQ: GSUN) shares surged 92.1% to settle at $52.89 on Friday.
Benzinga · 09/26 07:43
Why Shares Of Oil & Gas Companies Are Trading Lower, Here Are 62 Stocks Moving In Friday's Mid-Day Session
Gainers Kiromic BioPharma, Inc. (NASDAQ: KRBP) shares jumped 87% to $0.4791. Kiromic BioPharma, said on Sept. 15, that the company received letter from the Nasdaq that co. has been granted 180-day extension to March 13, 2023 to regain compliance.
Benzinga · 09/23 16:16
Recent Selloff Is A 'Buying Opportunity' For This NASH Stock, Says Analyst
Benzinga · 09/16 18:05
What 4 Analyst Ratings Have To Say About Altimmune
Over the past 3 months, 4 analysts have published their opinion on Altimmune (NASDAQ:ALT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Benzinga · 09/16 17:07
Expert Ratings for Altimmune
Analysts have provided the following ratings for Altimmune (NASDAQ:ALT) within the last quarter:
Benzinga · 09/16 14:13
Altimmune defended at H.C. Wainwright ahead of key readout for obesity drug
After topline data for a live disease candidate led to a massive selloff in Altimmune, Inc. (NASDAQ:<a href="https://seekingalpha.com/symbol/ALT?utm_medium=referral&utm_source=webull.com" title="Altimmune, Inc."...
Seekingalpha · 09/16 14:10
Guggenheim Maintains Buy on Altimmune, Lowers Price Target to $26
Guggenheim analyst Seamus Fernandez maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $31 to $26.
Benzinga · 09/16 12:28
More
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and are in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany and Spain, and conducting Its pemvidutide Phase I clinical trial in Australia. Its wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Webull offers kinds of Altimmune Inc stock information, including NASDAQ:ALT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALT stock methods without spending real money on the virtual paper trading platform.